search
subscribe by email
Twitter
-
Recent Posts
current comments
topics
- #RunningAtlas (1)
- Adaptive Sports (1)
- Atlas Venture (36)
- Bioentrepreneurship (36)
- Biotech financing (101)
- Biotech investment themes (47)
- Biotech startup advice (65)
- Boards and governance (14)
- Boston Cluster (13)
- Business Development (44)
- Capital efficiency (25)
- Capital markets (48)
- Corporate Culture (52)
- Diagnostics (2)
- Drug discovery (26)
- Exits IPOs M&As (126)
- External R&D (15)
- FDA (3)
- From The Trenches (254)
- Fundraising (15)
- General Venture Capital (46)
- Governance (2)
- Leadership (34)
- Marketing (1)
- New business models (34)
- Patients (11)
- Personal (2)
- Personalized Medicine (4)
- Pharma industry (73)
- Portfolio news (64)
- Pricing and Policy (5)
- R&D Productivity (23)
- Rare Diseases (12)
- Science & Medicine (49)
- Strategy (4)
- Talent (53)
- The Human Element (9)
- Translational research (41)
- Uncategorized (24)
- VC-backed Biotech Returns (67)
monthly archive
- December 2024 (1)
- November 2024 (1)
- October 2024 (2)
- September 2024 (2)
- August 2024 (2)
- July 2024 (3)
- June 2024 (2)
- May 2024 (4)
- April 2024 (4)
- March 2024 (3)
- February 2024 (2)
- January 2024 (4)
- November 2023 (3)
- October 2023 (2)
- September 2023 (1)
- August 2023 (1)
- July 2023 (2)
- June 2023 (1)
- May 2023 (1)
- April 2023 (2)
- March 2023 (3)
- February 2023 (3)
- January 2023 (1)
- December 2022 (2)
- November 2022 (3)
- October 2022 (3)
- September 2022 (1)
- August 2022 (1)
- July 2022 (2)
- June 2022 (4)
- May 2022 (2)
- April 2022 (4)
- March 2022 (7)
- February 2022 (2)
- January 2022 (2)
- November 2021 (5)
- October 2021 (1)
- September 2021 (1)
- August 2021 (2)
- July 2021 (5)
- June 2021 (3)
- May 2021 (3)
- April 2021 (6)
- March 2021 (3)
- January 2021 (2)
- December 2020 (3)
- November 2020 (1)
- October 2020 (6)
- September 2020 (2)
- August 2020 (2)
- July 2020 (3)
- June 2020 (3)
- May 2020 (3)
- April 2020 (6)
- March 2020 (6)
- February 2020 (1)
- January 2020 (1)
- December 2019 (3)
- November 2019 (2)
- October 2019 (2)
- September 2019 (2)
- August 2019 (2)
- July 2019 (1)
- May 2019 (7)
- April 2019 (6)
- March 2019 (1)
- February 2019 (6)
- January 2019 (5)
- December 2018 (1)
- November 2018 (2)
- October 2018 (8)
- September 2018 (4)
- August 2018 (1)
- July 2018 (1)
- June 2018 (4)
- May 2018 (3)
- April 2018 (4)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (3)
- November 2017 (4)
- October 2017 (6)
- September 2017 (4)
- August 2017 (2)
- July 2017 (1)
- June 2017 (5)
- May 2017 (4)
- April 2017 (1)
- March 2017 (5)
- February 2017 (2)
- January 2017 (7)
- December 2016 (3)
- November 2016 (4)
- October 2016 (3)
- September 2016 (6)
- August 2016 (5)
- July 2016 (3)
- June 2016 (6)
- May 2016 (5)
- April 2016 (4)
- March 2016 (7)
- February 2016 (5)
- January 2016 (6)
- December 2015 (6)
- November 2015 (3)
- October 2015 (4)
- September 2015 (5)
- August 2015 (3)
- July 2015 (3)
- June 2015 (4)
- May 2015 (6)
- April 2015 (6)
- March 2015 (7)
- February 2015 (7)
- January 2015 (5)
- December 2014 (4)
- November 2014 (3)
- October 2014 (7)
- September 2014 (5)
- August 2014 (5)
- July 2014 (4)
- June 2014 (6)
- May 2014 (5)
- April 2014 (5)
- March 2014 (6)
- February 2014 (4)
- January 2014 (5)
- December 2013 (3)
- November 2013 (2)
- October 2013 (4)
- September 2013 (3)
- August 2013 (1)
- July 2013 (2)
- June 2013 (2)
- May 2013 (4)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Tag Archives: CRISPR/Cas
Riding The Gene Editing Wave: Reflections On CRISPR/Cas9’s Impressive Trajectory
May 31, 2016
CRISPR/Cas genome editing has captured the attention of the popular media, scientific community, and the investment world: the promise of going into a cell and precisely making changes in their genetic code to cure them of illness is certainly captivating.
